A5010486501- Cardiac Valve Diseases and Treatments
- Aortic Disease and Treatment Approaches
- Infective Endocarditis Diagnosis and Management
- Aortic aneurysm repair treatments
- Cardiac, Anesthesia and Surgical Outcomes
- Cardiac Structural Anomalies and Repair
- Cardiac and Coronary Surgery Techniques
- Cardiovascular Function and Risk Factors
- Immunotherapy and Immune Responses
- Congenital Heart Disease Studies
- Mechanical Circulatory Support Devices
- Immune Cell Function and Interaction
- Cardiac Arrest and Resuscitation
- Infectious Aortic and Vascular Conditions
- Antimicrobial Resistance in Staphylococcus
- Atrial Fibrillation Management and Outcomes
- Cardiac Imaging and Diagnostics
- Orthopedic Infections and Treatments
- Immune cells in cancer
- Renal and Vascular Pathologies
- Pericarditis and Cardiac Tamponade
- COVID-19 and healthcare impacts
- Otolaryngology and Infectious Diseases
- Cardiac pacing and defibrillation studies
- Vascular Procedures and Complications
Harvard University
2017-2025
Massachusetts General Hospital
2017-2025
University Medical Center Freiburg
2023
Boston University
2022
University of Pennsylvania
2007-2019
Society of Thoracic Surgeons
2011-2018
African Organisation for Research and Training in Cancer
2018
Universitäts-Herzzentrum Freiburg-Bad Krozingen
2017
University of Freiburg
2017
Hospital of the University of Pennsylvania
2016
Abstract Purpose: Myeloid suppressor (Gr-1+/CD11b+) cells accumulate in the spleens of tumor-bearing mice where they contribute to immunosuppression by inhibiting function CD8+ T and promoting tumor angiogenesis. Elimination these myeloid may thus significantly improve antitumor responses enhance effects cancer immunotherapy, although date few practical options exist. Experimental Design: The effect chemotherapy drug gemcitabine on number animals bearing large tumors derived from five lines...
Randomized data comparing outcomes of transcatheter aortic valve replacement (TAVR) with surgery in low–surgical risk patients at time points beyond 2 years is limited. This presents an unknown for physicians striving to educate as part a shared decision-making process. The authors evaluated 3-year clinical and echocardiographic from the Evolut Low Risk trial. Low-risk were randomized TAVR self-expanding, supra-annular or surgery. primary endpoint all-cause mortality disabling stroke several...
5,6-Dimethylxanthenone-4-acetic acid (DMXAA) is a small molecule in the flavanoid class that has antitumor activity thought to be due ability induce high local levels of tumor necrosis factor (TNF)-alpha disrupt established blood vessels within tumors. The drug completed phase 1 testing humans and currently 2 trials combination with chemotherapy. Although characterized as "vascular disrupting agent," there are some studies suggesting DMXAA also effects on immune system important for its...
Background— Proponents of flexible annuloplasty rings have hypothesized that such devices maintain annular dynamics. This hypothesis is based on the supposition motion relatively normal in patients undergoing mitral valve repair. We dynamics are impaired ischemic regurgitation and myxomatous regurgitation. Methods Results— A Philips iE33 echocardiographic module X7–2t probe were used to acquire full-volume real-time 3-dimensional transesophageal echocardiography loops 11 subjects, with Image...
Successful immunotherapy will require alteration of the tumour microenvironment and/or decreased immune suppression. Tumour-associated macrophages (TAMs) are one major factor affecting microenvironment. We hypothesised that altering TAM phenotype would augment efficacy immunotherapy. and others have reported 5,6-Dimethylxanthenone-4-acetic-acid (DMXAA, Vadimezan) has ability to change phenotypes, inducing a conducive antitumour responses. therefore combined DMXAA with active immunotherapies,...
Pulmonary hypertension (pHTN) is associated with increased risk of mortality after mitral valve surgery for regurgitation. However, its association clinical outcomes in patients undergoing transcatheter repair (TMVr) a commercially available system (MitraClip) unknown.To assess the pHTN readmissions heart failure and 1-year all-cause TMVr.This retrospective cohort study analyzed 4071 who underwent TMVr MitraClip from November 4, 2013, through March 31, 2017, across 232 US sites Society...
Given reports that the chemotherapeutic agent gemcitabine (GEM) does not block T-lymphocyte recall responses and is detrimental to specific anti-tumor immunity, studies evaluate use of GEM in combination with immunotherapy were initiated. When we tested therapeutic effects as a single various murine tumor models, found dose had impressive activity subset tumors. Surprisingly, efficacy was related vitro drug sensitivity, but instead, correlated immunogenicity tumor. A key role immune system...
Loss-of-function mutations in genes encoding contractile proteins have been observed thoracic aortic aneurysms (TAA). To gain insight into the contribution of protein deficiency pathogenesis TAA, we examined human aneurysm samples. We found multiple gene products deficient TAA samples, and particular, expression SM22α was inversely correlated with size. SM22α-deficient mice demonstrated pregnancy-induced dissection, worsened Fbn1C1039G/+ (Marfan) mice, validating this product as a effector....